163 related articles for article (PubMed ID: 12009950)
1. A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.
Hamblett KJ; Kegley BB; Hamlin DK; Chyan MK; Hyre DE; Press OW; Wilbur DS; Stayton PS
Bioconjug Chem; 2002; 13(3):588-98. PubMed ID: 12009950
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Park SI; Shenoi J; Frayo SM; Hamlin DK; Lin Y; Wilbur DS; Stayton PS; Orgun N; Hylarides M; Buchegger F; Kenoyer AL; Axtman A; Gopal AK; Green DJ; Pagel JM; Press OW
Clin Cancer Res; 2011 Dec; 17(23):7373-82. PubMed ID: 21976541
[TBL] [Abstract][Full Text] [Related]
3. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
4. Biotin reagents for antibody pretargeting. 2. Synthesis and in vitro evaluation of biotin dimers and trimers for cross-linking of streptavidin.
Wilbur DS; Pathare PM; Hamlin DK; Weerawarna SA
Bioconjug Chem; 1997; 8(6):819-32. PubMed ID: 9404654
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
Wilbur DS; Park SI; Chyan MK; Wan F; Hamlin DK; Shenoi J; Lin Y; Wilbur SM; Buchegger F; Pantelias A; Pagel JM; Press OW
Bioconjug Chem; 2010 Jul; 21(7):1225-38. PubMed ID: 20597486
[TBL] [Abstract][Full Text] [Related]
6. Energetic roles of hydrogen bonds at the ureido oxygen binding pocket in the streptavidin-biotin complex.
Klumb LA; Chu V; Stayton PS
Biochemistry; 1998 May; 37(21):7657-63. PubMed ID: 9601024
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of biotin-dye conjugates for use in an HPLC assay to assess relative binding of biotin derivatives with avidin and streptavidin.
Wilbur DS; Pathare PM; Hamlin DK; Frownfelter MB; Kegley BB; Leung WY; Gee KR
Bioconjug Chem; 2000; 11(4):584-98. PubMed ID: 10898581
[TBL] [Abstract][Full Text] [Related]
8. Effects of tryptophan residue fluorination on streptavidin stability and biotin-streptavidin interactions via molecular dynamics simulations.
Panek JJ; Ward TR; Jezierska A; Novic M
J Mol Model; 2009 Mar; 15(3):257-66. PubMed ID: 19052784
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Foulon CF; Bigner DD; Zalutsky MR
Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
[TBL] [Abstract][Full Text] [Related]
10. Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity.
Wilbur DS; Hamlin DK; Buhler KR; Pathare PM; Vessella RL; Stayton PS; To R
Bioconjug Chem; 1998; 9(3):322-30. PubMed ID: 9576806
[TBL] [Abstract][Full Text] [Related]
11. Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.
Wilbur DS; Hamlin DK; Meyer DL; Mallett RW; Quinn J; Vessella RL; Press OW
Bioconjug Chem; 2002; 13(3):611-20. PubMed ID: 12009953
[TBL] [Abstract][Full Text] [Related]
12. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
13. Streptavidin-biotin binding energetics.
Stayton PS; Freitag S; Klumb LA; Chilkoti A; Chu V; Penzotti JE; To R; Hyre D; Le Trong I; Lybrand TP; Stenkamp RE
Biomol Eng; 1999 Dec; 16(1-4):39-44. PubMed ID: 10796983
[TBL] [Abstract][Full Text] [Related]
14. Temperature control of biotin binding and release with A streptavidin-poly(N-isopropylacrylamide) site-specific conjugate.
Ding Z; Long CJ; Hayashi Y; Bulmus EV; Hoffman AS; Stayton PS
Bioconjug Chem; 1999; 10(3):395-400. PubMed ID: 10346869
[TBL] [Abstract][Full Text] [Related]
15. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
Schultz J; Lin Y; Sanderson J; Zuo Y; Stone D; Mallett R; Wilbert S; Axworthy D
Cancer Res; 2000 Dec; 60(23):6663-9. PubMed ID: 11118050
[TBL] [Abstract][Full Text] [Related]
16. Development of new biotin/streptavidin reagents for pretargeting.
Wilbur DS; Pathare PM; Hamlin DK; Stayton PS; To R; Klumb LA; Buhler KR; Vessella RL
Biomol Eng; 1999 Dec; 16(1-4):113-8. PubMed ID: 10796993
[TBL] [Abstract][Full Text] [Related]
17. Effect of endogenous biotin on the applications of streptavidin and biotin in mice.
Rusckowski M; Fogarasi M; Fritz B; Hnatowich DJ
Nucl Med Biol; 1997 Apr; 24(3):263-8. PubMed ID: 9228661
[TBL] [Abstract][Full Text] [Related]
18. Engineered streptavidin monomer and dimer with improved stability and function.
Lim KH; Huang H; Pralle A; Park S
Biochemistry; 2011 Oct; 50(40):8682-91. PubMed ID: 21892837
[TBL] [Abstract][Full Text] [Related]
19. A monovalent streptavidin with a single femtomolar biotin binding site.
Howarth M; Chinnapen DJ; Gerrow K; Dorrestein PC; Grandy MR; Kelleher NL; El-Husseini A; Ting AY
Nat Methods; 2006 Apr; 3(4):267-73. PubMed ID: 16554831
[TBL] [Abstract][Full Text] [Related]
20. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
